Immunotherapy for Leukemia Targeting the Wilms' Tumor Gene

References

• Call K. M., Glaser T., Ito C. Y., Buckler A. J., Pelletier J., Haber D. A., Rose E. A., Kral A., Yeger H., Lewis W. H., Jones C., Housman D E. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990; 60: 509–520
   PubMed Web of Science ®Google Scholar
• Gessler M., Poustka A., Cavenee W., Neve R. L., Orkin S. H., Bruns G. A.P. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 1990; 343: 774–778
   PubMed Web of Science ®Google Scholar
• Cashier A. L., Bonthron D. T., Madden S. L., Rauscher F. J., II, Collins I. T., Sukhatme V P. Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1. Proceedings of the National Academy of Sciences of the United States of America 1992; 89: 10984–10989
   PubMed Web of Science ®Google Scholar
• Drummond I. A., Madden S. L., Rohwer-Nutter P., Bell G. I., Sukhatme V. P., Rauscher F. J., III. Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1. Science 1992; 257: 674–678
   PubMed Web of Science ®Google Scholar
• Harrington M. A., Konicek B., Song A., Xia X., Fredericks W. J., Rauscher F. J., III. Inhibition of colony-stimulating factor-1 promoter activity by the product of the Wilms' tumor locus. Journal of Biological Chemistry 1993; 268: 21271–21275
   PubMed Web of Science ®Google Scholar
• Dey B. R., Sukhatme V. P., Roberts A. B., Sporn M. B., Rauscher F. J., III, Kim S J. Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product. Molecular Endocrinology 1994; 8: 595–602
   PubMed Web of Science ®Google Scholar
• Goodyer P., Dehbi M., Torban E., Bruening W., Pelletier I. Repression of the retinoic acid receptor-alpha gene by the Wilms' tumor suppressor gene product, wt1. Oncogene 1995; 16: 1125–1129
   Google Scholar
• Hewitt S. M., Hamada S., McDonnell T. J., Rauscher F. J., III, Saunders G F. Regulation of the proto-oncogene bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1. Cancer Research 1995; 55: 5386–5389
   PubMed Web of Science ®Google Scholar
• Pritchard-Jones K., Fleming S., Davidson D., Bickmore W., Porteous D., Gosden C., Bard J., Buckler A., Pelletier J., Housman D., van Heyningen V., Hastie N. The candidate Wilms' tumour gene is involved in genitourinary development. Nature 1990; 346: 194–197
   PubMed Web of Science ®Google Scholar
• Huang A., Campbell C. E., Bonetta L., McAndrews-Hill M. S., Chilton-MacNeill S., Coppes M. J., Law D. J., Feinberg A. P., Yeger H., Williams B. R.G. Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor. Science 1990; 250: 991–994
   PubMed Web of Science ®Google Scholar
• Kreidberg J. A., Sariola H., Loring J. M., Maeda M., Pelletier I., Housman D., Jaenisch R. WT1 is required for early kidney development. Cell 1993; 74: 679–691
   PubMed Web of Science ®Google Scholar
• Park S., Schalling M., Bernard A., Maheswaran S., Shipley G. C., Roberts D., Fletcher J., Shipman R., Rheinwald J., Demetri G., Griffin J., Minden M., Housman D. E., Haber D A. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nature Genetics 1993; 4: 415–420
   PubMed Web of Science ®Google Scholar
• Pelletier J., Schalling M., Buckler A. J., Rogers A., Haber D. A., Housman D E. Expression of the Wilms' tumor gene WT1 in the murine urogenital system. Genes and Development 1991; 5: 1345–1356
   PubMed Web of Science ®Google Scholar
• Miwa H., Beran M., Saunders G F. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992; 6: 405–409
   PubMed Web of Science ®Google Scholar
• Miyagi T., Ahuja H., Kubota T., Kubonishi I., Koeffler H. P., Miyoshi I. Expression of the candidate Wilms' tumor gene, WT1 in human leukemia cells. Leukemia 1993; 7: 970–977
   PubMed Web of Science ®Google Scholar
• Menssen H. D., Renkl H. J., Rodeck U., Maurer J., Notter M., Schwartz S., Reinhardt R., Thiel E. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995; 9: 1060–1067
   PubMed Web of Science ®Google Scholar
• Baird P. N., Simmons P J. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Experimental Hematology 1997; 25: 312–320
   PubMed Web of Science ®Google Scholar
• Maurer U., Brieger J., Weidmann E., Mitrou P. S., Hoelzer D., Bergmann L. The Wilms' tumor gene is expressed in a subset of CD34+ progenitors and downregulated early in the course of differentiation in vitro. Experimental Hematology 1997; 25: 945–950
   PubMed Web of Science ®Google Scholar
• Schmid D., Heinze G., Linnerth B., Tisljar K., Kusec R., Geissler K., Sillaber C., Laczika K., Mitterbauer M., Zöchbauer S., Mannhalter C., Haas O. A., Lechner K., Jäger U., Gaiger A. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997; 11: 639–643
   PubMed Web of Science ®Google Scholar
• Bergmann L., Miething C., Maurer U., Brieger J., Karakas T., Weidmann E., Hoelzer D. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 1997; 90: 1217–1225
   PubMed Web of Science ®Google Scholar
• Inoue K., Sugiyama H., Ogawa H., Nakagawa M., Yamagami T., Miwa H., Kita K., Hiraoka A., Masaoka T., Nasu K., Kyo T., Dohy H., Nakauchi H., Ishidate T., Akiyama T., Kishimoto T. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84: 3071–3079
   PubMed Web of Science ®Google Scholar
• Tamaki H., Ogawa H., Ohyashiki K., Ohyashiki J. H., Iwama H., Inoue K., Soma T., Oka Y., Tatekawa T., Oji Y., Tsuboi A., Kim E. H., Kawakami M., Fuchigami K., Tomonaga M., Toyama K., Aozasa K., Kishimoto T., Sugiyama H. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndrome. Leukemia 1999; 13: 393–399
   PubMed Web of Science ®Google Scholar
• Inoue K., Ogawa H., Yamagami T., Soma T., Tani Y., Tatekawa T., Oji Y., Tamaki H., Kyo T., Dohy H., Hiraoka A., Masaoka T., Kishimoto T., Sugiyama H. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood 1996; 88: 2267–2278
   PubMed Web of Science ®Google Scholar
• Yamagami T., Sugiyama H., Inoue K., Ogawa H., Tatekawa T., Hirata M., Kudoh T., Akiyama T., Murakami A., Maekawa T., Kishimoto T. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87: 2878–2884
   PubMed Web of Science ®Google Scholar
• Algar E. M., Khromykh T., Smith S. I., Blackburn D. M., Bryson G. J., Smith P J. A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12: 1005–1014
   PubMed Web of Science ®Google Scholar
• Ohminami H., Yasukawa M., Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000; 95: 286–293
   PubMed Web of Science ®Google Scholar
• Maurer U., Weidmann E., Karakas T., Hoelzer D., Bergmann L. Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors. Blood 1997; 90: 4230–4231
   PubMed Web of Science ®Google Scholar
• Oka Y., Elisseeva O. A., Tsuboi A., Ogawa H., Tamaki H., Li H., Oji Y., Kim E. H., Soma T., Asada M., Ueda K., Maruya E., Saji H., Kishimoto T., Udaka K., Sugiyama H. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1) product. Immunogenetics 2000; 51: 99–107
   PubMed Web of Science ®Google Scholar
• Gao L., Bellantuono I., Elsässer A., Marley S. B., Gordon M. Y., Goldman J. M., Stauss H J. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95: 2198–2203
   PubMed Web of Science ®Google Scholar
• Oka Y., Udaka K., Tsuboi A., Elisseeva O. A., Ogawa H., Aozasa K., Kishimoto T., Sugiyama H. Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Journal of Immunology 2000; 164: 1873–1880
   PubMed Web of Science ®Google Scholar
• Viel A., Giannini F., Capozzi E., Canzonieri V., Scarabelli C., Gloghini A., Boiocchi M. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. International Journal of Cancer 1994; 57: 515–521
   PubMed Web of Science ®Google Scholar
• Langerak A. W., Williamson K. A., Miyagawa K., Hagemeijer A., Versnel M. A., Hastie N D. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Gene, Chromosomes & Cancer 1995; 12: 87–96
   PubMed Web of Science ®Google Scholar
• Amin K. M., Litzky L. A., Smythe W. R., Mooney A. M., Morris J. M., Mews D. J.Y., Pass H. I., Kari C., Rodeck U., Rauscher F. J., III., Kaiser L. R., Albelda S M. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in human malignant mesothelioma. American Journal of Pathology 1995; 146: 344–356
   PubMed Web of Science ®Google Scholar
• Campbell C. E., Kuriyan N. P., Rackley R. R., Caulfield M. J., Tubbs R., Finke J., Williams B. R.G. Constitutive expression of the Wilms tumor suppresor gene (WT1) in renal cell carcinoma. International Journal of Cancer 1998; 78: 182–188
   PubMed Web of Science ®Google Scholar
• Oji Y., Ogawa H., Tamaki H., Oka Y., Tsuboi A, Kim E. H., Soma T., Tatekawa T., Kawakami M., Asada M., Kishimoto T., Sugiyama H. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Japanese Journal of Cancer Research 1999; 90: 194–204
   PubMedGoogle Scholar
• Tsuboi A., Oka Y., Ogawa H., Elisseeva O. A., Li H., Kawasaki K., Aozasa K., Kishimoto T., Udaka K., Sugiyama H. Cytotoxic T-lymphocyte response elicited to Wilms' tumor gene WT1 product by DNA vaccination. Journal of Clinical Immunology 2000; 20: 195–202
   PubMed Web of Science ®Google Scholar